GlobalData, the industry analysis specialist, has released its latest report, “CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Turkey”. The report is an essential source of information on and analysis of the healthcare, regulatory and reimburseme ..."
BMI View: Turley will remain one of the largest markets in Central and Eastern Europe for both
healthcare expenditure and pharmaceutical sales, boosted by a growing and ageing population with a high
prevalence of non-communicable diseases. A poor regulatory environmen ..."
BMI View: A strong healthcare sector and more certain drug pricing policy will drive pharmaceutical sales
in value terms over the next 10 years and improve the commercial opportunities for pharmaceutical
manufacturers. Despite this positive development, cost containme ..."
BMI View: A strong health care sector and more certain drug pricing policy will drive pharmaceutical
sales in value terms over the next 10 years and improve the commercial opportunities for pharmaceutical
manufacturers. Despite this positive development, cost containm ..."
BMI View: New medicine pricing rules introduced by the Turkish government will enable drugmakers to
raise their prices following years of price suppression. We expect these changes to boost pharmaceutical
sales in value terms over the next 10 years and improve the com ..."
Turkey is exhibiting a healthy economy, driven by government incentive programs and initiatives supporting public-private partnerships. These programs and initiatives have been key in sustaining growth in Turkey and supporting a better economic environment compared to the rest ..."
BMI View: Turkey's pharmaceutical and healthcare markets will continue to grow over the long term due
to underlying fundamentals driving demand for healthcare services, its population dynamics, increasing
urban migration and the burden of disease in the country. In co ..."
BMI View: Turkey possesses all the key growth fundamentals for an attractive pharmaceutical sector, but
heavy regulatory oversight will stifle growth over the short term. Over the longer term, we expect the
regulatory burden to lessen and become more amenable to the s ..."
BMI View: Despite a challenging pricing and reimbursement situation compounded by currency
uncertainty, BMI still believes the Turkish pharmaceutical market is attractive in the long term as higher yo-
y growth rates return from 2013/14. In contrast to European market ..."
BMI View: Data released by the Turkish drugmakers association for 2013 sales corresponds with our own
forecasts. We have also modified our pharmaceutical sales forecast for 2014 and beyond to reflect the
volatile exchange rate situation. We now see Turkey's lustre as ..."